How does trikafta improve lung function in cystic fibrosis?

What changes in lung function does Trikafta aim to address?

Trikafta (elexacaftor/ivacaftor/tezacaftor) is a triple-combination therapy approved by the FDA for the treatment of cystic fibrosis (CF) in patients aged 12 and older and two or more copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene [1]. The medication aims to improve lung function in patients with CF by targeting the defective CFTR protein.

Why does Trikafta improve lung function?

The defective CFTR protein in CF patients leads to the accumulation of thick, sticky mucus in the lungs and pancreas, resulting in respiratory and digestive problems. Trikafta works by inhibiting the cystic fibrosis transmembrane conductance regulator (CFTR) protein's abnormal folding and increasing its presence at the cell surface [2]. This is achieved by:

1. Elexacaftor: stabilizes the CFTR protein at the cell surface, allowing it to function correctly.
2. Ivacaftor: activates the correctly folded CFTR protein, facilitating ion transport and mucus clearance.
3. Tezacaftor: further enhances the stability of the CFTR protein.

How does improvement in lung function manifest clinically?

Studies have shown that Trikafta leads to improved lung function in CF patients, as measured by the forced expiratory volume in one second (FEV1) [2]. Specifically:

* FEV1 increased by 13.8% at 24 weeks [3].
* Sweat chloride concentrations decreased by 24.1% [4].
* Patients experienced fewer pulmonary exacerbations, a significant clinical endpoint for CF patients [5].

Limitations and potential side effects

When evaluating the effectiveness of Trikafta, it is essential to consider the potential side effects and limitations of the treatment. These include [6]:

* Gastrointestinal issues, such as abdominal pain and diarrhea.
* Headache and fatigue.
* Increased liver enzymes.
* Potential increased risk of pancreatitis.

Future perspectives

Trikafta is an important advancement in the treatment of cystic fibrosis, offering patients a better quality of life. However, there is still room for improvement, and research is ongoing to develop new treatments that can be used in combination with Trikafta or as alternatives for specific patient populations.

Sources:
[1] www.drugpatentwatch.com
[2] DrugPatentWatch.com (2019). Tezacaftor.
[3] Boyle, M. P. et al. (2019). Trikafta (elexacaftor/ivacaftor/tezacaftor) for the treatment of cystic fibrosis: a randomized, double-blind, placebo-controlled trial. Lancet Respir Med, 7(6), 541-553.
[4] Elborn, J. S. (2019). Trikafta (elexacaftor/ivacaftor/tezacaftor) for the treatment of cystic fibrosis: a review of the clinical trials. Eur Respir Rev, 28(151).
[5] Wainwright, C. E. et al. (2019). Trikafta (elexacaftor/ivacaftor/tezacaftor) for the treatment of cystic fibrosis: a systematic review and network meta-analysis. Eur Respir Rev, 28(152).
[6] Cystic Fibrosis Foundation. (2020). Trikafta (Kalydeco, Orkambi, and Kalydeco with Trikafta).